AFT Pharmaceutical flags aggressive two-year revenue target
AFT Pharmaceuticals boosts revenue, but profits still lag Telix Pharmaceuticals chair and CEO reflect on a prosperous 2024 – and promise more riches to come Dimerix’s pivotal trail passes another safety check The bourse's ‘forgotten’ drug maker, Kiwi- …